

FORM PTO-1390 (REV. 10-2003) modified		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 3039 USOP	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NO. (if known, see 37 CFR 1.52) 10/510396	
INTERNATIONAL APPLICATION NO. PCT/JP03/04396		INTERNATIONAL FILING DATE April 7, 2003		PRIORITY DATE CLAIMED April 8, 2002	
TITLE OF INVENTION SEVERE SEPSIS PREVENTIVE THERAPEUTIC AGENT					
APPLICANT(S) FOR DO/EO/US Masayuki II, Yuji IIZAWA, Tomoyuki KITAZAKI, Kazuki KUBO					
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input checked="" type="checkbox"/> The US has been elected (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is attached hereto.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4).</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <p>a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau).</p> <p>b. <input type="checkbox"/> have been communicated by the International Bureau.</p> <p>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input checked="" type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).</p> <p>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>Items 11 to 20 below concern document(s) or information included:</p> <p>11. <input checked="" type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98. Cited References</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A preliminary amendment.</p> <p>14. <input type="checkbox"/> An Application Data Sheet under 37 CFR 1.76.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A power of attorney and/or change of address letter.</p> <p>17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input checked="" type="checkbox"/> Other items or information: FIGURES 1-6</p> <p>Itemized Return Postcard; Certificate of Express Mailing; Express Mail Label No. 524906075 US</p> <p>PCT Request; Forms PCT/IB/301, 304, 308; Cover Page Date of Deposit October 7, 2004</p> <p>International Application; ISR</p>					

FORM PTO-1390 (REV 10-2003) page 2 of 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE 10596

Application No.:	Based on PCT/JP03/04396	Art Unit:	tba
Filed:	Intl. Filing 07 APRIL 2003	Examiner:	tba
1 st Inventor:	II, Masayuki	Allowed:	
For:	Severe Sepsis Preventive Therapeutic Agent	Batch:	
Atty. Dkt. No.	3039 USOP	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**USPS EXPRESS MAIL LABEL. No. EV 524906075 US****DATE IN: October 7, 2004****Itemized Papers/Items:**


1. This Certificate and Return Postcard (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Specification - total pages (122) including Claims 1-20 (pages 107-115, Abstract (1 page), and Drawings (6 pages)
4. PCT Request (5 pages)
5. Copies of Forms PCT/IB/301, 304, 308 (4 pages)
6. Copy of Cover Page International Application (WO 03/084527) (1 page)
7. Copy of International Search Report (4 pages)
8. Preliminary Amendment (3 pages)
9. Information Disclosure Statement (1 page), Form PTO/SB/08A and 08B (3 pages), cited references (10)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

MAIL STOP PCT
P.O. BOX 1450
Commissioner for Patents
Alexandria, VA 22313-1450

on this date, 10/ 7 /04

Dated: 10/7/04


Dawn Hackbert

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
475 Half Day Road
Lincolnshire, IL 60069 USA